Inoviv is pleased to bring together leading drug developers and industry experts to discuss NeuroKey-3™, a recent advancement in disease-targeted LC-MS biomarker assays for coverage of key Alzheimer’s disease (AD) and Dementia markers in human plasma. The discussion will be led by Inoviv’s Commercial SVP, Ben Gonzales, and Chief Scientific Officer, Ernestas Sirka.